Company: GMRE
Filing Date: 2025-11-13
Form Type: 424B5
Source: 0001104659-25-110926
Chunk: 0

Company: Global Medical REIT Inc.
Filing Date: 2025-11-13
Form: 424B5
Chunk 0
---
Filed Pursuant to Rule 424(b)(5)
Registration No. 333-276248

This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, as amended, but is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

<div align='center'>SUBJECT TO COMPLETION, DATED NOVEMBER 13, 2025</div>

PRELIMINARY PROSPECTUS SUPPLEMENT

(To prospectus dated April 4, 2024)

<div align='center'>Shares

% Series B Cumulative Redeemable Preferred Stock</div>

Global Medical REIT Inc. (“we,” “us,”
“our” or the “Company”) is an internally-managed real estate investment trust (“REIT”) that acquires
healthcare facilities and leases those facilities to physician groups and regional and national healthcare systems. We are selling
shares of our % Series B Cumulative Redeemable Preferred Stock, $0.001
par value per share (“Series B Preferred Stock”), in this offering. This is the original issuance of shares of our Series B
Preferred Stock, which will have a liquidation preference of $25.00 per share.

Holders of Series B Preferred Stock will
be entitled to receive dividend payments only when, as and if declared by the board of directors of the Company (the “Board of Directors”)
or a duly authorized committee of the Board of Directors. Any such dividends will be payable in cash from the original issuance date on
a cumulative basis, quarterly in arrears on January 31, April 30, July 31 and October 31 of each year, commencing
on January 31, 2026 to holders of record as of January 15, 2026. The dividend rate of %
per annum will be applied to the liquidation preference of $25.00 per share (equivalent to $
per share per annum). Payment of dividends on the Series B Preferred Stock is subject to certain legal and other restrictions as
described elsewhere in this prospectus supplement.

We may, at our option, redeem the Series B
Preferred Stock for cash in whole or in part, from time to time, at any time on or after , 2030, as described under “Description
of Series B Preferred Stock